Get the Stockscreener App
7.81
9.82%
-0.85
After Hours:
8.27
0.46
+5.89%
Cullinan Therapeutics Inc stock is traded at $7.81, with a volume of 755.24K.
It is down -9.82% in the last 24 hours and up +32.37% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
See More
Previous Close:
$8.66
Open:
$8.57
24h Volume:
755.24K
Relative Volume:
0.88
Market Cap:
$461.37M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-2.1165
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
-3.10%
1M Performance:
+32.37%
6M Performance:
-11.15%
1Y Performance:
-50.51%
1-Day Range:
$7.76
$8.77
1-Week Range:
$7.55
$8.7796
52-Week Range:
$5.68
$17.50
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
7.81 | 511.58M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-21-25 | Resumed | H.C. Wainwright | Buy |
| Jun-11-25 | Resumed | Stifel | Buy |
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Cullinan Therapeutics (CGEM) Reveals Promising Phase 1 Data for CLN-049 in AML and MDS - GuruFocus
Cullinan Therapeutics Inc. stock daily chart insights2025 AllTime Highs & Free Technical Confirmation Trade Alerts - newser.com
Cullinan Management Unveils Promising CLN-049 Clinical Data - TipRanks
Heatmap analysis for Cullinan Therapeutics Inc. and competitorsMarket Weekly Review & Verified Entry Point Signals - newser.com
Cullinan Therapeutics Presents New Data on CLN-049 at ASH Meeting - TradingView
Cullinan (NASDAQ: CGEM) announces 69% ORR for CLN-049 in r/r AML; Phase 1 shows manageable safety - Stock Titan
Cullinan Therapeutics Inc. stock trend forecastMarket Performance Summary & Weekly High Potential Alerts - newser.com
Can Cullinan Therapeutics Inc. stock attract ESG capital inflowsQuarterly Performance Summary & Daily Market Momentum Tracking - newser.com
Using data filters to optimize entry into Cullinan Therapeutics Inc.Swing Trade & Technical Pattern Based Buy Signals - newser.com
Visual analytics tools that track Cullinan Therapeutics Inc. performanceWeekly Volume Report & Weekly Chart Analysis and Guides - newser.com
Cullinan Therapeutics Inc. stock outlook for YEARJuly 2025 Movers & High Conviction Trade Alerts - newser.com
Is Cullinan Therapeutics Inc. reversing from oversold territory2025 Bull vs Bear & Risk Controlled Stock Pick Alerts - newser.com
Can Cullinan Therapeutics Inc. stock beat market expectations this quarterGold Moves & Low Drawdown Momentum Trade Ideas - newser.com
What machine learning models say about Cullinan Therapeutics Inc.2025 Top Decliners & Reliable Price Breakout Alerts - newser.com
Will Cullinan Therapeutics Inc. rebound enough to break evenWeekly Earnings Recap & Safe Entry Momentum Tips - newser.com
What makes Cullinan Therapeutics Inc. stock attractive to growth fundsQuarterly Profit Report & AI Driven Price Forecasts - newser.com
Backtesting results for Cullinan Therapeutics Inc. trading strategies2025 Volume Leaders & Real-Time Volume Analysis - newser.com
Why retail investors pile into Cullinan Therapeutics Inc. stockProduct Launch & Free Reliable Trade Execution Plans - newser.com
Will Cullinan Therapeutics Inc. stock gain from government policiesEarnings Overview Summary & Reliable Price Breakout Alerts - newser.com
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 13.5% After Insider Buying Activity - MarketBeat
Will Cullinan Therapeutics Inc. stock return to pre crisis levelsQuarterly Earnings Report & Verified Trade Idea Suggestions - newser.com
What momentum indicators show for Cullinan Therapeutics Inc. stockJuly 2025 Breakouts & AI Enhanced Trade Execution Alerts - newser.com
Cullinan Therapeutics (NASDAQ:CGEM) Major Shareholder Lynx1 Capital Management Lp Purchases 165,667 Shares - MarketBeat
Cullinan Therapeutics (CGEM) Projected to Post Earnings on Thursday - MarketBeat
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):